Grimes & Company, Inc. Vertex Pharmaceuticals Inc Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
A detailed history of Grimes & Company, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Grimes & Company, Inc. holds 630 shares of VRTX stock, worth $283,733. This represents 0.01% of its overall portfolio holdings.
Number of Shares
630
Previous 629
0.16%
Holding current value
$283,733
Previous $294,000
0.34%
% of portfolio
0.01%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding VRTX
# of Institutions
1,723Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.1 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.4 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.6 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.32 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.05 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $116B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...